Skip to content
Medical Health Aged Care

APNA Media Alert for Friday 26 July, 2024

The Australian Primary Health Care Nurses Association (APNA) < 1 mins read

Over 1000 health care professionals from all across the country will attend today’s Australian Primary Health Care Nurses Association (APNA) Essential Health Summit and Primary Heatlh Care Congress (Friday 26th July 2024) where funding to create the next generation of Australian nurses will be announced by Assistant Minister for Health and Aged Care the Hon Ged Kearney.

 

 

 

What: APNA Essential Health Summit and Primary Health Care Congress.

 

Who: Assistant Minister for Health and Aged Care Ged Kearney; Member for Boothby Louise Miller-Frost MP; APNA President Karen Booth; APNA CEO Ken Griffin; Australian College of Nurse Practitioners (ACNP) President Melanie Dunstan; three student nurses and one nurse facilitator.

 

When: 9.30 am setup, Friday 26 July, 2024.

 

Where: West Entry, Level 1, City Rooms, Adelaide Exhibition and Convention Centre.

 


About us:

About The Australian Primary Health Care Nurses Association (APNA)

 

APNA represents over 96,000 primary health care nurses in Australia working outside of

hospitals, including those employed in general practice, schools, aged care facilities,

correctional facilities and in wider community settings.

 


Contact details:

Media contact:

Sue Bellino 0400 1888 25

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.